Get the Stockscreener App
6.805
3.68%
-0.255
Diamedica Therapeutics Inc stock is traded at $6.805, with a volume of 48,291.
It is down -3.68% in the last 24 hours and down -3.82% over the past month.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
See More
Previous Close:
$7.06
Open:
$7.12
24h Volume:
48,291
Relative Volume:
0.14
Market Cap:
$351.48M
Revenue:
-
Net Income/Loss:
$-19.90M
P/E Ratio:
-12.84
EPS:
-0.53
Net Cash Flow:
$-19.80M
1W Performance:
-1.16%
1M Performance:
-3.82%
6M Performance:
+60.76%
1Y Performance:
+60.00%
1-Day Range:
$6.79
$7.178
1-Week Range:
$6.64
$7.178
52-Week Range:
$3.19
$7.4899
Diamedica Therapeutics Inc Stock (DMAC) Company Profile
Name
Diamedica Therapeutics Inc
Sector
Industry
Phone
(763) 496-5454
Address
301 CARLSON PARKWAY, MINNEAPOLIS, MN
Compare DMAC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DMAC
Diamedica Therapeutics Inc
|
6.80 | 364.92M | 0 | -19.90M | -19.80M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.98 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.24 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.40 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
824.45 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
181.60 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Diamedica Therapeutics Inc Stock (DMAC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-30-25 | Initiated | TD Cowen | Buy |
| Oct-07-24 | Initiated | H.C. Wainwright | Buy |
| Apr-24-24 | Resumed | Craig Hallum | Buy |
| Jun-22-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-09-21 | Initiated | Oppenheimer | Outperform |
| Feb-17-21 | Initiated | ROTH Capital | Buy |
| Oct-30-20 | Initiated | Guggenheim | Buy |
| Jul-08-20 | Initiated | Maxim Group | Buy |
| Apr-30-19 | Initiated | Dougherty & Company | Buy |
| Mar-05-19 | Initiated | Lake Street | Buy |
View All
Diamedica Therapeutics Inc Stock (DMAC) Latest News
Is DiaMedica Therapeutics Inc. still worth holding after the dipMarket Activity Summary & Community Consensus Stock Picks - newser.com
What momentum shifts mean for DiaMedica Therapeutics Inc.2025 Momentum Check & Risk Adjusted Swing Trade Ideas - newser.com
Will DiaMedica Therapeutics Inc. stock reach Wall Street targetsJuly 2025 PostEarnings & Stepwise Swing Trade Plans - newser.com
Developing predictive dashboards with DiaMedica Therapeutics Inc. dataEarnings Miss & Safe Swing Trade Setups - newser.com
Short interest data insights for DiaMedica Therapeutics Inc.Weekly Earnings Recap & Weekly Return Optimization Alerts - newser.com
Can DiaMedica Therapeutics Inc. stock hit analyst price targetsTrade Risk Assessment & Capital Efficiency Focused Ideas - newser.com
Has DiaMedica Therapeutics Inc. formed a bullish divergenceQuarterly Profit Report & Risk Managed Investment Strategies - newser.com
Is DiaMedica Therapeutics Inc. stock cheap at current valuation2025 Year in Review & Fast Moving Stock Trade Plans - newser.com
Will DiaMedica Therapeutics Inc. stock attract ESG investorsMarket Volume Summary & Low Risk Entry Point Guides - newser.com
How institutional buying supports DiaMedica Therapeutics Inc. stockGap Up & Community Consensus Stock Picks - newser.com
Will DiaMedica Therapeutics Inc. stock outperform tech sector in 2025IPO Watch & Long-Term Capital Growth Strategies - newser.com
Smart tools for monitoring DiaMedica Therapeutics Inc.’s price actionCEO Change & Weekly Market Pulse Updates - newser.com
Can DiaMedica Therapeutics Inc. stock double in next 5 years2025 Technical Patterns & Low Drawdown Investment Ideas - newser.com
Can DiaMedica Therapeutics Inc. stock outperform in 2025 bull marketJuly 2025 News Drivers & Weekly Chart Analysis and Trade Guides - newser.com
Published on: 2025-11-01 02:03:37 - newser.com
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
DiaMedica Therapeutics (NASDAQ:DMAC) Coverage Initiated at TD Cowen - MarketBeat
Why Wall Street Experts Believe This Biotech Stock Represents a Major Opportunity - Barchart.com
Sector ETF performance correlation with DiaMedica Therapeutics Inc.Trade Risk Summary & Risk Controlled Stock Pick Alerts - newser.com
Published on: 2025-10-31 05:34:37 - newser.com
Why DiaMedica Therapeutics Inc. stock remains on watchlistsQuarterly Market Summary & Technical Pattern Recognition Alerts - newser.com
Live market analysis of DiaMedica Therapeutics Inc.Quarterly Trade Summary & Risk Managed Investment Signals - newser.com
What valuation multiples suggest for DiaMedica Therapeutics Inc. stockJuly 2025 Drop Watch & Low Drawdown Trading Techniques - newser.com
Visual analytics tools that track DiaMedica Therapeutics Inc. performanceJuly 2025 Reactions & Safe Capital Growth Tips - newser.com
Order flow analysis tools used on DiaMedica Therapeutics Inc.2025 Volatility Report & AI Powered Buy/Sell Recommendations - newser.com
DiaMedica Therapeutics stock initiated with Buy rating at TD Cowen By Investing.com - Investing.com South Africa
DiaMedica Therapeutics stock initiated with Buy rating at TD Cowen - Investing.com
Diamedica Therapeutics Inc Stock (DMAC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Diamedica Therapeutics Inc Stock (DMAC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| STAHLBERG JAN | 10% Owner |
Aug 13 '25 |
Buy |
5.91 |
293,601 |
1,734,918 |
7,058,066 |
| STAHLBERG JAN | 10% Owner |
Aug 14 '25 |
Buy |
5.99 |
70,414 |
421,921 |
7,128,480 |
| STAHLBERG JAN | 10% Owner |
Aug 20 '25 |
Buy |
5.86 |
71,107 |
416,495 |
7,207,820 |
| STAHLBERG JAN | 10% Owner |
Aug 26 '25 |
Buy |
6.00 |
59,648 |
357,888 |
7,713,693 |
| STAHLBERG JAN | 10% Owner |
Aug 22 '25 |
Buy |
5.96 |
59,788 |
356,576 |
7,315,780 |
| STAHLBERG JAN | 10% Owner |
Aug 27 '25 |
Buy |
6.00 |
50,772 |
304,632 |
7,764,465 |
| STAHLBERG JAN | 10% Owner |
Aug 21 '25 |
Buy |
5.96 |
48,172 |
287,028 |
7,255,992 |
| STAHLBERG JAN | 10% Owner |
Aug 15 '25 |
Buy |
6.00 |
8,233 |
49,398 |
7,136,713 |
| STAHLBERG JAN | 10% Owner |
Jul 23 '25 |
Buy |
3.50 |
1,542,857 |
5,400,000 |
6,764,465 |
| Von Koch Thomas | 10% Owner |
Jul 23 '25 |
Buy |
3.50 |
2,857,142 |
9,999,997 |
8,383,577 |
0.68%
0.96%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):